Sibylle Bischofberger
Sibylle Bischofberger is an analyst at Vontobel, where she specializes in the evaluation and analysis of pharmaceutical companies, including Bachem. In a recent assessment, she highlighted the challenges faced by Bachem, particularly regarding delays in the expansion of their production capacity, which have negatively impacted investor sentiment despite the company's strong market position in peptide manufacturing.
Not in the pool (under ¢1).
Recent news mentions
Sibylle Bischofberger, an analyst at Vontobel, believes that Sonova will gain market shares despite the challenging environment.
Schweizer Aktien: Sonova braucht noch Zeit
Switzerland· 2025-12-07
Sibylle Bischofberger emphasized that all major pharmaceutical companies are present in the USA and have announced extensive investments for the coming years.
Warum die Börse gelassen bleibtSwitzerland· 2025-09-27
Sibylle Bischofberger is an analyst who has closely followed Tecan and commented on the company's market challenges.
Für einen Einstieg ist es noch zu frühSwitzerland· 2025-08-14
Sibylle Bischofberger is an analyst at Vontobel and comments on Ypsomed's focus on niche markets.
Helvetia-Baloise-Fusion: Grätscht Zurich noch dazwischen?Switzerland· 2025-04-25
Sibylle Bischofberger summarizes the situation of Bachem, noting that the market is disappointed with the delays in expanding production capacity.
Bachem ist ein klarer Kauf – zumindest langfristigSwitzerland· 2025-03-20